Fas expression in conjunctival epithelial cells of patients with cystic fibrosis

Journal of Interferon and Cytokine Research

Volumn 29, Issue 11, 2009, Pages 735-739

  Mrugacz, Malgorzata ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMPRESSION CYTOLOGY; INFLAMMATORY CELL; LACRIMAL FLUID; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

ADOLESCENT; ANTIGENS, CD95; APOPTOSIS; CELL SEPARATION; CELLS, CULTURED; CHILD; CONJUNCTIVA; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; MALE; MUTATION; TEARS; YOUNG ADULT;

EID: 73649139586     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0111     Document Type: Article

References (38)

1. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA. 1995. Fas ligand mediated activation induced cell death in human T lymphocytes. J Exp Med 181:71-77.
2. Amsellem C, Durieu I, Chambe MT, Peyrol S, Pacheco Y. 2002. In vitro expression of Fas and CD40 and induction of apoptosis in human cystic fibrosis airway epithelial cells. Respir Med 96:244-249.
3. Baudouin C. 2001. The pathology of dry eye. Surv Ophthalmol 45:211-220.
4. Baudouin C, Liang H. 2005. Amplifying factors in ocular surface diseases: apoptosis. Ocul Surf 3:194-197.
5. Brignole F, Pisella PJ, Goldschild M, de Saint-Jean M. 2000. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci 41:1356-1363.
6. Brignole F, Pisella PJ, de Saint-Jean M, Goldschild M, Goguel A, Baudouin C. 2002. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 42:90-95.
7. Brignole F, de Saint-Jean M, Goldschild M, Becquet F, Goguel A, Baudouin C. 1998. Expression of Fas-Fas ligand antigens and apoptotic marker APO2.7 by the human conjunctival epithelium: positive correlation with class II HLA DR expression in inflammatory ocular surface disorders. Exp Eye Res 67:687-697.
8. Buttke TM, Sandstrom PA. 1994. Oxidative stress as a mediator of apoptosis. Immunol Today 15:7-10.
9. Castagna I, Roszkowska AM, Fama F, Sinicropi S, Ferreri G. 2001. The eye in cystic fibrosis. Eur J Ophthalmol 11:9-14.
10. Cheng J, Zhou T, Liu C. 1994. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762.
11. De Saint-Jean M, Brignole F, Feldmann G, Goguel A, Baudouin C. 1999. Interferon-ã induces apoptosis and expression of inflammation- related proteins in Chang conjunctival cells. Invest Ophthalmol Vis Sci 40:2199-2212.
12. Durieu I, Amsellem C, Paulin C, Chambe MT, Bienvenu J, Bellon G. 1999. Fas and Fas ligand expression in cystic fibrosis airway epithelium. Thorax 54:1093-1098.
13. Gao J, Schwalb TA, Addeo JV, Ghosn CR, Stern ME. 1998. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical cyclosporin A therapy. Cornea 17:654-663.
14. Goldman MJ, Mark Anderson G, Stolzenberg ED. 1997. Human β-defensin-1 is a salt sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553-560.
15. Gottlieb RA, Dosanjh A. 1996. Mutant cystic fibrosis transmembrane conductance regulator inhibits acidifi cation and apoptosis in C127 cells: possible relevance to cystic fibrosis. Proc Natl Acad Sci USA 93:3587-3591.
16. Griffi th TS, Brunner T, Flechter SM. 1995. Fas ligand-induced apoptosis as a mechanism of immune tolerance. Science 270: 1189-1192.
17. Hasunuma T, Kayagaki N, Asahara H. 1997. Accumulation of soluble Fas in inflammed joints of patients with rheumatoid arthritis. Arthritis Rheum 40:80-86.
18. Konan KV, Taylor MW. 1996. Treatment of ME180 cells with interferon- gamma causes apoptosis as a result tryptophan starvation. J Interferon Cytokine Res 16:751-756.
19. Leithauseur F, Dhein J, Mechtersheimer G. 1993. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415-429.
20. Maiuri L, Raia V, De Marco G. 1997. DNA fragmentation is a feature of cystic fibrosis epithelial cells: a disease with inappropriate apoptosis? FEBS Lett 408:225-231.
21. McKechnie NM, King BCR, Braun G. 2006. Fas ligand is stored in secretory lysosomes of ocular barrier epithelia and released with microvesicles. Exp Eye Res 83:304-314.
22. McKone EF, Emerson SS, Edwards KL, Aitken ML. 2003. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 361:1671-1676.
23. Meredith JE, Fazeli JB, Schwartz MA. 1993. The extracellular matrix as a cell survival factor. Mol Biol Cell 4:953-961.
24. Mrugacz M, Minarowska A, Bakunowicz-Łazarczyk A, Zywalewska N. 2004. Dry eye syndrome in children with cystic fibrosis. Med Wieku Rozwoj 8:865-870.
25. Nagata S, Golstein P. 1995. The Fas death factor. Science 267:1449-1456.
26. Nakamura S. 1997. Cell biology in endogenous uveitis. J Jpn Ophthalmol Soc 263:975-986.
27. Niehans GA, Brunner T, Frizelle SP. 1997. Human lung carcinomas express Fas ligand. Cancer Res 57:1007-1012.
28. Pflugfelder SC. 2004. Dysfunction of the integrated functional unit-impact on tear film stability and composition. In: Pflugfelder SC, Stern ME, Beuerman RW, eds. Dry eye and the ocular surface- a unified approach. New York: Marcel Dekker. pp. 63-68.
29. Riodan JR, Rommens JM, Kerem BS. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066-1073.
30. Stern ME, Beuerman RW, Fox RI. 1998. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol 438:643-651.
31. Streilein JW. 1999. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res 18:357-370.
32. Streilein JW. 2003. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 3:879-889.
33. Sugita S, Taguchi T, Takase H, Sagawa K, Sueda J, Fukushi K. 2000. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis. Br J Ophthalmol 84:1130-1134.
34. Suss G, Shortman K. 1996. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 183:1789-1796.
35. Turner HC, Bernstein A, Candia O. 2002. Presence of CFTR in the conjunctival epithelium. Curr Eye Res 24:182-187.
36. Van Lopik T, Bijl M, Hart M. 1999. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse. J Rheumatol 26:60-67.
37. Welsh MJ, Anderson MP, Rich DP. 1993. Cystic fibrosis, CFTR and abnormal electrolyte transport. In: Davis PB, ed. Cystic fibrosis. New York: Marcel Dekker. pp. 29-52.
38. Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder S. 2003. Apoptosis of ocular surface in experimentally induced dry eye. Invest Ophthalmol Vis Sci 44:124-129.